A PHASE 1, OPEN-LABEL, MULTI-CENTER, NON-RANDOMIZED STUDY OF [F-18]SMS-5368 POSITRON EMISSION TOMOGRPHY IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL RECURRENCE AND NEGATIVE CONVENTIONAL IMAGING

被引：0
|
作者：
Hatcher, Paul A.
Culp, Stephen H.
von Gall, Carl C.
Osborne, Dustin R.
Fu, Yitong
Smith, William B.
Moolupuri, Abhi
Whitaker, Dustin L.
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP18-10
引用
收藏
页码：E304 / E304
页数：1
相关论文
共 43 条
  • [21] A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Kelly, William Kevin
    Hussain, Arif
    Saraiya, iren
    Thanigaimani, Pradeep
    Sun, Furong
    Seebach, Frank A.
    Lawy, Israel
    Sandigursky, Sabina
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (6_SUPPL) : TPS282 - TPS282
  • [22] A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
    K. H. Park
    S. Lee
    J. H. Park
    S. Y. Kang
    H. Y. Kim
    I. H. Park
    Y. H. Park
    Y. H. Im
    H. J. Lee
    S. Park
    S.I. Lee
    K.H. Jung
    Y.S. Kim
    Jae Hong Seo
    Supportive Care in Cancer, 2017, 25 : 505 - 511
  • [23] A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Calvo, Mariona
    Penkov, Konstantin
    Spira, Alexander I.
    Candilejo, Irene Moreno
    Shore, Neal D.
    Zhang, Tian
    Mellado-Gonzalez, Begona
    Gordoa, Teresa Alonso
    Rodriguez, Luis Paz-Ares
    Tarantolo, Stefano R.
    Soto, Juan Jose
    Alter, Robert S.
    Andreu-Vieyra, Claudia
    Bowler, Timothy
    Maity, Arnab K.
    Hariharan, Subramanian
    Schweizer, Michael Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [24] A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
    Park, K. H.
    Lee, S.
    Park, J. H.
    Kang, S. Y.
    Kim, H. Y.
    Park, I. H.
    Park, Y. H.
    Im, Y. H.
    Lee, H. J.
    Park, S.
    Lee, S. I.
    Jung, K. H.
    Kim, Y. S.
    Seo, Jae Hong
    SUPPORTIVE CARE IN CANCER, 2017, 25 (02) : 505 - 511
  • [25] ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
    Laccetti, Andrew Leonard
    Smith, Matthew Raymond
    Scher, Howard I.
    Verholen, Frank
    Adorjan, Patrick
    Dissanayake, Manjari
    Gao, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS243 - TPS243
  • [26] A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)
    Loibl, Sibylle
    Barinoff, Jana
    Seiler, Sabine
    Decker, Thomas
    Denkert, Carsten
    Hardy-Bessard, Anne-Claire
    Senkus-Konefka, Elzbieta
    Cognetti, Francesco
    Palmieri, Carlo
    Gelmon, Karen
    Luebbe, Kristina
    Furlanetto, Jenny
    Mueller, Volkmar
    Mundhenke, Christoph
    Schmidt, Marcus
    von Minckwitz, Gunter
    Uhlig, Mathias
    Burchardi, Nicole
    Thill, Marc
    CANCER RESEARCH, 2018, 78 (04)
  • [27] Methodology of EARLIMS Study: A Multi-Center, Open-Label, Non-Randomized, Parallel Group Clinical Trial To Assess the Efficacy of Fingolimod in Treatment-Naive Patients Versus Fingolimod in Patients Previously Treated with Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients with Relapsing-Remitting Multiple Sclerosis
    Montalban, Xavier
    Fernandez, Oscar
    Luisa Gobartt, Ana
    NEUROLOGY, 2012, 78
  • [28] 18F-Choline PET/CT and conventional imaging vs. conventional imaging alone in patients with intermediate and high prostate cancer before curative intent therapy (IOV-PR-CH-1-2013): a prospective, open, randomized, multicenter study
    Evangelista, L.
    Bertin, D.
    Borsatti, E.
    Trifiro, G.
    Brugola, E.
    Farsad, M.
    Trenti, E.
    Chierichetti, F.
    Donner, D.
    Bartolomei, M.
    Urso, L.
    Cracco, E.
    Gallan, M.
    Setti, L.
    Bombardieri, E.
    Del Bianco, P.
    Magni, G.
    De Salvo, G. L.
    Novara, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S482 - S483
  • [29] An open-label, randomized, multi-center phase 2 study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2-breast cancer (MBC) with an ESR1 mutation
    Plourde, P. V.
    Schwartzberg, L. S.
    Greene, G. L.
    Portman, D. J.
    Komm, B. S.
    Jenkins, S. N.
    Liu, P-Y
    Portman, M. D.
    Goetz, M. P.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
    K. H. Park
    J. H. Sohn
    S. Lee
    J. H. Park
    S. Y. Kang
    H. Y. Kim
    I. H. Park
    Y. H. Park
    Y. H. Im
    H. J. Lee
    D. S. Hong
    S. Park
    S. H. Shin
    H. C. Kwon
    J. H. Seo
    Investigational New Drugs, 2013, 31 : 1300 - 1306
12345